Funding

>

Latest News

GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease
GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease

May 14th 2025

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.

Michelle Hoffmann, PhD
How Chicago is Strategizing Around NIH Funding Cuts: Q&A with Michelle Hoffmann

April 28th 2025

Merida Biosciences Launches with $121 Million in Series A Financing to Develop Precision Therapeutics for Autoimmune, Allergic Diseases
Merida Biosciences Launches with $121 Million in Series A Financing to Develop Precision Therapeutics for Autoimmune, Allergic Diseases

April 10th 2025

Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement

April 1st 2025

Merck Reaches Licensing Agreement with Jiangsu Hengrui for Novel Heart Disease Drug
Merck Reaches Licensing Agreement with Jiangsu Hengrui for Novel Heart Disease Drug

March 25th 2025

More News